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ABSTRACT
Dengue is an arboviral infection clinically recognized as an acute and self-limited disease. 
Persistence of dengue symptoms is known, but it has been little studied. The aim of this study 
was to characterize persistent symptoms in 113 patients with dengue followed up clinically 
and by laboratory testing at a tertiary hospital. Symptoms that persisted for more than 14 days 
were observed in 61 (54.0%) patients, and six (6.2%) of them had symptoms for 6 months or 
more. The persistent symptoms identified were myalgia, weakness, hair loss, memory loss, 
reduced resistance to physical effort, headache, reasoning problems, arthralgia, sleepiness- and 
emotional lability. The progression to persistent symptoms was significantly associated with 
hospitalization, older age, more severe disease, the presence of bleeding and comorbidities 
upon univariate analysis. Upon multivariate analysis, the presence of persistent symptoms 
continued to be significantly associated only with increased age and dengue with warning 
signs. The platelet count during the acute phase of the disease was significantly lower in the 
group with persistent symptoms. In conclusion, the frequency of progression to persistent 
symptoms in dengue is relevant in patients seen at a tertiary hospital and the persistence of 
symptoms is more common in patients with dengue with warning signs. 
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INTRODUCTION
Dengue is a viral disease transmitted by arthropods that occurs in more than 
100 countries and whose incidence has been increasing over the past 50 years1. In 
2013, based on the identification of 58.4 million cases of dengue worldwide, the 
aggregate global cost of the disease was estimated to be US$ 8.9 billion2. However, 
this number is probably underestimated because the additional costs resulting from 
the persistence of dengue symptoms in part of the affected population were not 
considered3.
Dengue fever is characterized as an acute febrile disease that lasts 1 to 2 weeks4. 
However, literature data have called attention to the persistence of symptoms and 
laboratory alterations after the acute phase. Isolated cases of persistent symptoms 
were reported-and they were attributed to complications of the disease within specific 
contexts such as myositis5,6 and persistent thrombocytopenia7. Another study found 
that the persistence of symptoms is not a rare event, such as the occurrence of 
post-infectious fatigue syndrome in 27% (31/127) of patients evaluated 2 months 
after the diagnosis of dengue8. Using different study designs, several authors have 
reported a wide variability in the prevalence of persistent symptoms according to 
the type of symptom, form of assessment and time of follow-up9-12.
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The present study prospectively investigated patients 
with dengue attended and followed up at a university 
hospital in Brazil to evaluate the persistence of symptoms 
and factors associated with this evolution.
PATIENTS AND METHODS
Patients
Patients seen at the University Hospital of the Federal 
University of Triângulo Mineiro (HC/UFTM), Uberaba, 
Minas Gerais, Brazil, between January 2012 and May 2015, 
were included. 
The criteria for inclusion were age older than 14 years 
(minimum age of admission to the emergency department 
of the Clinic of HC/UFTM); hospitalized and/or receiving 
outpatient care (at least one outpatient visit) at the 
HC/UFTM; clinical suspicion of dengue recorded on the 
chart; positive serology for dengue (ELISA IgM or NS1) - 
and agreement to participate in the study. 
Patients who died were not included in the study since it 
was not possible to evaluate persistent symptoms of dengue 
in this group. The research was approved by the Ethics 
Committee of UFTM in 2011, Process Nº 1966. 
Serological diagnosis
The ELISA IgM and NS1 assays were carried out at the 
referral services of the municipality, at the Macroregional 
Reference Laboratory and at the HC/UFTM using kits 
provided by the Brazilian Ministry of Health. All results 
were confirmed in the computerized exam registration 
system of the State of Minas Gerais (Gerenciador de 
Ambiente Laboratorial/GAL/Fundação Ezequiel Dias).
Clinical data
The signs and symptoms of the patients were 
systematically investigated using a specific clinical chart 
to characterize the acute phase of the disease (up to 14 
days from the onset of symptoms). Spontaneous complaints 
were recorded and the patients were then asked about 
the presence of the following signs/symptoms and their 
respective duration: fever, headache, retro-orbital pain, 
myalgia, exanthema, prostration, arthralgia, nausea, 
vomiting, diarrhea, sleepiness, weakness, coryza- and 
cough. The patients were also questioned about spontaneous 
bleeding, warning signs (intense abdominal pain, persistent 
vomiting, painful hepatomegaly, pre-syncope, mucosal 
bleeding, sleepiness/irritability, and respiratory distress), 
date of onset and duration, and presence of signs of shock 
(hypotension, cold extremities, cyanosis, and rapid pulse). 
Information about the presence of comorbidities, history of 
medication use, allergies, and personal history of diseases 
was also obtained. Comorbidities were identified based on 
the patient’s self-report, complementary tests, and previous 
medical follow-up. 
In the case of patients hospitalized at the HC/UFTM, 
the records were reviewed to search for warning signs and 
signs of shock identified during medical care. Data reported 
by the patient were compared to those recorded during 
hospitalization at the HC/UFTM.
The participants underwent outpatient follow-up 
consisting of at least one weekly visit up to one month 
after the onset of symptoms and a monthly visit while the 
patient continued to report any symptom related to the 
disease. Additional visits were scheduled according to the 
clinical needs of patients. Another specific chart was used 
during the outpatient follow-up to record the spontaneous 
complaints of the patients and then applying the objective 
inquiry about the presence of fever, headache, retro-orbital 
pain, myalgia, exanthema, prostration, arthralgia, nausea, 
vomiting, diarrhea, sleepiness, weakness, coryza, cough, 
hair loss, cognitive state, memory loss, reasoning problems 
and skin changes. The objective signs were extracted from 
a survey of symptoms reported in a previous study10. All 
visits were conducted by at least one of the two participating 
physicians. 
For the analysis, the presence of persistent symptoms 
of dengue was defined as the identification of previously 
non-existing symptoms lasting more than 14 days, which 
were attributed to the disease by the patient. Signs and 
symptoms that occurred up to two weeks of the disease 
onset were associated with the acute phase.
Laboratory data
The results of blood counts and liver tests (aspartate 
aminotransferase - AST, and alanine aminotransferase – 
ALT) performed at the HC/UFTM during the follow-up of 
patients at the institution were requested. The number of 
repetitions of each test, the most altered value found and the 
day of disease on which the worst result was obtained were 
recorded. The results were collected using the Esmeralda 
computerized laboratory information system installed at 
the HC/UFTM.
The normal reference values for leukocytes were 4,000 
to 10,000 cells/mm3. Hematocrit was considered to be 
altered when < 30% for both genders, or > 50% for men 
and > 44% for women13. For platelets, values of 150,000 to 
500,000 platelets/mm3 were considered normal. The liver 
enzymes results were compared to the reference values and 
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an increase was expressed as the number of times the result 
exceeds the upper limit of the reference range. 
Classification of dengue
The patients of the study were classified into three 
groups: dengue, dengue with warning signs, and severe 
dengue. Since cases of dengue without fever have been 
recognized, dengue was considered when a clinical suspicion 
was made by the attending physician associated with a 
positive serological test. The parameters recommended 
by the World Health Organization (WHO)14 and by the 
Brazilian Ministry of Health13 were used for the groups 
classified as dengue with warning signs and severe dengue. 
Thus, the “dengue with warning signs” group was defined 
as the presence of dengue accompanied by at least one of 
the following signs/symptoms: severe abdominal pain, 
persistent vomiting, painful hepatomegaly, pre-syncope, 
bleeding, sleepiness/irritability, mucosal bleeding, and 
respiratory distress. The “severe dengue” group was defined 
as the presence of signs of shock (postural hypotension, cold 
extremities, cyanosis, and rapid pulse), severe hemorrhage 
(hematemesis and melena), and severe organ dysfunction 
(e.g., respiratory failure). 
Data analysis
The association between each clinical parameter and the 
presence of persistent symptoms was evaluated using the 
classical chi-square test or Fisher exact test. The strength 
of the association was measured by calculating relative 
risks (RR) with 95% confidence intervals (95% CI). Age 
was compared in relation to the clinical parameters using 
the nonparametric Mann-Whitney or Kruskal-Wallis test, 
followed by the Dunn test. The statistical analyses were 
performed using the Statistica 10.0 software (Statsoft, 
Tulsa, OK, 2011) and MedCalc 12.2 programs (MedCalc 
Software, Ostend, Belgium). The level of significance was 
set at p<0.05. 
RESULTS
During the study period, 176 subjects with suspicion 
of dengue were seen at the HC/UFTM. Of these, 51 had 
no diagnostic confirmation (27 did not undergo serological 
testing and did not return to the service, 21 had negative 
serology and the ELISA IgM result was indeterminate in 3). 
In addition, of the 125 patients with a confirmed diagnosis of 
dengue, 7 died and 5 attended only one medical visit. Thus, 
113 patients were followed up during the study until medical 
discharge and all of them presented clinical suspicion and 
serological diagnostic confirmation (93 positive ELISA 
IgM and 20 positive NS1). 
Of the 113 patients included in the study, 49 (43.4%) were 
hospitalized at the HC/UFTM, which is a tertiary hospital. 
The most frequent reason for admission was evidence 
of bleeding accompanied or not by thrombocytopenia in 
35 patients (31.0%). There was agreement between the 
warning signs and signs of shock reported by the patients 
and those recorded during hospitalization at the HC/UFTM. 
The presence of persistent symptoms was observed in 61 
(54.0%) of the patients in this study. Demographic data of 
patients are shown in Table 1.
Table 1 - Demographic data of the 113 patients with dengue 
in the study
Characteristics n %
Gender
Male 42 37.2
Female 71 62.8
Age (years)
14-30 43 38.1
30-60 55 48.7
> 60 15 13.3
Hospitalization
No 62 54.9
Yes 49 43.4
Unknown 2 1.8
Classification of dengue
Dengue 62 54.9
Dengue with warning signs 45 39.8
Severe dengue 6 5.3
Reason for hospitalization
Bleeding/thrombocytopenia 35 31.0
Abdominal pain/hepatomegaly 19 16.8
Pre-syncope/lethargy/mental confusion/
sleepiness
8 7.1
Respiratory distress 8 7.1
Persistent vomiting 7 6.2
Shock/signs of shock 4 3.5
Respiratory failure 3 2.7
Other 4 3.5
Comorbidity
No 49 43.4
Yes 63 55.8
Unknown 1 0.9
Persistent symptoms
No 52 46.0
Yes 61 54.0
Teixeira et al.
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Evaluation of the initial symptoms of dengue showed 
that only 100 (88.5%) of the patients reported fever. The 
most common symptom was weakness accompanied or not 
by prostration, reported by 111 (98.2%) of the participants. 
The frequency of the other signs and symptoms was 
headache in 100 (88.5%) patients, nausea in 86 (76.1%), 
retro-orbital pain in 75 (66.4%), exanthema in 71 (62.8%), 
sleepiness in 71 (62.8%), arthralgia in 63 (55.8%), diarrhea 
in 55 (48.7%), vomiting in 39 (34.5%), cough in 34 (30.1%), 
abdominal pain in 23 (20.4%), coryza in 19 (16.8%), and 
pruritus in 18 (15.9%).
Myalgia and weakness were the two most common 
symptoms during the acute phase of the disease and among 
the persistent symptoms. Recurrent symptoms that had not 
been previously established in the directed interview were 
identified. The most common symptoms were reduced 
resistance to physical effort and emotional lability. In 
the 61 patients with persistent symptoms, the duration 
of symptoms ranged from 1 to 12 months. Symptoms 
persisted for up to one month in 27 (44.3%) patients, for 
2 to 5 months in 27 (44.3%), and for 6 months or more in 
7 (11.5%) patients. No specific therapeutic intervention 
was performed and the symptoms resolved over time. 
The main persistent signs and symptoms of the disease 
are listed in Table 2.
The presence of comorbidities and persistent symptoms 
increased significantly with age (Table 3). The most 
frequent comorbidities were systemic arterial hypertension 
in 19 (30.2%) patients, hypothyroidism in 9 (14.3%) and 
diabetes mellitus in 6 (9.5%) patients. All comorbidities 
are described in Table 4. 
A total of 481 blood counts, 283 AST measurements 
and 272 ALT measurements were obtained from the 113 
patients followed up in this study. 
During the acute phase of the disease, an altered 
hematocrit value was observed in only 17 (15%) patients, 
including 12 (10.6%) with increased hematocrit and five 
with low hematocrit, associated with severe bleeding. 
Among the 45 patients classified as dengue with warning 
signs, 39 (87%) had no altered hematocrit value. 
Thrombocytopenia was observed in 80 (71%) patients and 
was more common on day 6 of the disease. Leukopenia 
was present in 66 (58%) patients and was more common 
Table 2 - Most common persistent symptoms shown by the 
patients during the study
Most common 
persistent 
symptoms
% Among all 
patients 
(n=113)
% Among patients 
with persistent 
symptoms (n=61)
Myalgia 25.7 47.5
Weakness 22.1 41.0
Hair loss 19.5 36.1
Memory loss 15.9 29.5
Reduced resistance 
to physical effort
15.0 27.9
Headache 13.3 24.6
Reasoning 
problems
13.3 24.6
Arthralgia 11.5 21.3
Sleepiness 10.6 19.7
Emotional lability 4.4 8.2
Table 3 - Association between age and clinical parameters in patients with dengue 
Clinical parameter
Age (years)
p-value
Mean (± SD) 1 Median  (minimum-maximum)
Classification of dengue
Dengue 39.2 ± 15.4 38.5 (17.0-80.0) 0.105
Dengue with warning signs 41.4 ± 19.2 39.0 (14.0-92.0)
Severe dengue 55.3 ± 18.0 57.5 (35.0-84.0)
Comorbidity
No 31.1 ± 12.1 27.0 (14.0-60.0) <0.001
Yes 48.6 ± 17.2 49.0 (17.0-92.0)
Persistent symptoms
No 32.9 ± 12.3 29.0 (14.0-64.0) <0.001
Yes 47.8 ± 17.6 48.0 (15.0-92.0)
1 The results are expressed as the mean ± standard deviation. 2 The p-value refers to the result of the nonparametric Mann-Whitney 
test for comparison between two independent samples (comorbidity, persistent symptoms), or of the Kruskal-Wallis test for com-
parison between three independent samples (WHO classification).
Rev Inst Med Trop São Paulo. 2017;59:e65
Prospective study of patients with persistent symptoms of dengue in Brazil
Page 5 of 9
Table 4 - Comorbidities shown by 63 patients in the study 
Comorbidity n %
Systemic arterial hypertension 8 12.7
Diabetes mellitus 3 4.8
Gastroesophageal reflux 3 4.8
Hypothyroidism 3 4.8
Aids 3 4.8
Dyslipidemia 2 3.2
Alcohol use disorder 1 1.6
Linfoma in remission 1 1.6
Glaucoma 1 1.6
Migraine 1 1.6
Cardiopathy, ischemic 1 1.6
Post bariatric surgery 1 1.6
Morbid obesity 1 1.6
Thyroid gland cancer 1 1.6
Chagas disease 1 1.6
Hydronephrosis 1 1.6
Idiopathic thrombocytopenic purpura 1 1.6
Vitiligo 1 1.6
Asthma 1 1.6
Pituitary adenoma 1 1.6
Depression 1 1.6
Prostatic hyperplasia 1 1.6
Systemic arterial hypertension and biliary lithiasis 1 1.6
Systemic arterial hypertension and aids 1 1.6
Systemic arterial hypertension and valve disease 1 1.6
Systemic arterial hypertension and hypothyroidism 1 1.6
Systemic arterial hypertension and chronic obstructive pulmonary disease 1 1.6
Systemic arterial hypertension and peptic ulcer disease 1 1.6
Epilepsy and arthrosis 1 1.6
Depression and meningitis sequela 1 1.6
Allergic rhinitis and hypothyroidism 1 1.6
Depression and chronic anemia 1 1.6
Hypoacusis and late-onset dementia 1 1.6
Hypoacusis and cardiac arrhythmia 1 1.6
Labyrinthitis and arthrosis 1 1.6
Psoriasis and hemorrhoids 1 1.6
Systemic arterial hypertension, congestive heart failure and chronic renal insufficiency 1 1.6
Systemic arterial hypertension, Chagas disease and breast cancer 1 1.6
Systemic arterial hypertension, breast cancer and arthrosis 1 1.6
Systemic arterial hypertension, diabetes mellitus and arthrosis 1 1.6
Systemic arterial hypertension, fibromyalgia and hypothyroidism 1 1.6
Diabetes mellitus, hypothyroidism and depression 1 1.6
Allergic rhinitis, sinusitis and recurrent otitis 1 1.6
Chronic myeloid leukemia, rhinitis and gastritis 1 1.6
Rheumatoid arthritis, Sjögren syndrome and fibromyalgia 1 1.6
Diabetes mellitus, hypothyroidism, osteoporosis and dyslipidemia 1 1.6
Epilepsy, hypothyroidism and chronic renal insufficiency 1 1.6
Teixeira et al.
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on day 4, elevated AST was observed in 68 (60%) and was 
more common on day 7, and elevated ALT was observed in 
63 (56%) and was more common on day 8 of the disease. 
A significant association was observed between altered 
hematocrit, AST and ALT and the dengue with warning 
signs (RR: 1.3; 1.8; 1.9, respectively) and severe dengue 
(RR: 8.2; 1.8; 2.4, respectively). When compared to the 
presence of persistent symptoms, the association was 
significant only with altered ALT (RR: 1.5) (Table 5).
The progression to persistent symptoms was significantly 
associated with older age (30-60 years RR: 2.2; > 60 years 
RR; 2.7), dengue with warning signs (RR: 2.1), severe 
dengue (RR: 2.4), hospitalization (RR: 1.5), presence of 
bleeding (RR: 1.6), respiratory discomfort (RR: 1.7), and 
comorbidities (RR: 1.6) (Table 6). 
DISCUSSION
The WHO, and consequently the Brazilian protocols that 
are based on its recommendation, defines the presence of 
fever accompanied by two or more of the following criteria 
as the diagnosis of probable dengue: nausea/vomiting, 
exanthema, myalgia, headache, positive tourniquet test 
or any warning sign13,14. In the present study, individuals 
with symptoms compatible with the disease, which led 
to a clinical suspicion by the attending physician even 
in the absence of fever, were considered suspected cases 
of dengue. In this respect, about 10% of all evaluated 
participants did not report fever and the diagnosis would 
not have been made if the classical definition of the disease 
would have been followed. On the other hand, of the 13 
individuals without fever, only in 3 of them the illness was 
confirmed by NS1 and in 10 by ELISA IgM. Considering 
that IgM has also been used in an unreported number of 
patients to establish the diagnosis of the disease and it can 
remain positive for some months, it is not possible to rule 
out the hypothesis of some other infection instead of dengue.
The prevalence of dengue with persistent symptoms 
reported in the literature varies widely, from 2 to 68%3. In 
contrast to a retrospective study previously published by our 
group, the prospective follow-up of patients in the present 
study provided more reliable information. Nevertheless, the 
prevalence of persistent symptoms was similar to that found 
in the previous retrospective study, 50-60%10.
The most common persistent symptoms of dengue 
reported in different studies were myalgia11, arthralgia15, 
and headache12. Other prevalent symptoms include 
weakness, adynamia, fatigue and asthenia8,9,11,12,15,16, 
whose duration can reach 2 years11. These symptoms were 
also the most frequent in the present study. However, the 
marked presence of other symptoms such as hair loss, 
memory loss, reasoning problems, sleepiness and emotional 
lability should be highlighted. The repercussions of these 
persistent symptoms on the work capacity and quality of 
life of affected individuals require further investigation17.
The global economic impact of dengue involves an 
Table 5 - Comparison between altered laboratory tests and the clinical parameter in patients with dengue
Clinical parameter
Altered laboratory test
Hematocrit Leukocytes Platelets Aspartate transaminase
Alanine 
transaminase
Persistent symptoms
No 5/49 (10.2%) 35/49 (71.4%) 37/49 (75.5%) 27/49 (55.1%) 22/49 (44.9%)
Yes 12/61 (19.7%) 36/60 (60.0%) 43/61 (70.5%) 41/61 (67.2%) 41/61 (67.2%)
RR (95% CI)1 1.9 (0.7-5.1) 0.8 (0.6-1.1) 0.9 (0.7-1.2) 1.2 (0.9-1.7) 1.5 (1.1-2.1)
p-value* 0.172 0.213 0.557 0.194 0.019
Clinical Classification
Dengue 6/59 (10.2%) 41/58 (70.7%) 41/59 (69.5%) 27/59 (45.8%) 23/59 (39.0%)
Dengue with warning signs 6/45 (13.3%) 26/45 (57.8%) 33/45 (73.3%) 36/45 (80.0%) 34/45 (75.6%)
Severe dengue 5/6 (83.3%) 4/6 (66.7%) 6/6 (100.0%) 5/6 (83.3%) 6/6 (100.0%)
RR (95% CI)2 1.3 (0.5-3.8) 0.8 (0.6-1.1) 1.1 (0.8-1.4) 1.8 (1.3-2.4) 1.9 (1.4-2.8)
RR (95% CI)3 8.2 (3.5-19.0) 0.9 (0.5-1.7) 1.3 (0.9-1.8) 1.8 (1.2-2.9) 2.4 (1.6-3.5)
p-value* <0.001 0.393 0.277 0.001 <0.001
* The p-value corresponds to the result of the chi-square test. For parameters with p<0.05. RR (95% CI)1 indicates the risk of 
individuals with a diagnosis of dengue and persistent symptoms to have altered laboratory tests compared to patients without 
persistent symptoms. RR (95% CI)2 indicates the risk of individuals with a diagnosis of dengue and warning signs to have altered 
laboratory tests compared to patients with dengue. RR (95% CI)3 indicates the risk of individuals with severe dengue to have altered 
laboratory tests compared to patients with dengue.
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Table 6 - Univariate analysis of the association between persistent symptoms and clinical variables 
Variables Presence of persistent 
symptoms RR (95% CI)1 p-value
Gender
Male 22/42 (52.4%) 1.0 0.793
Female 39/71 (54.9%) 1.1 (0.7-1.5)
Age (years)
< 30 13/43 (30.2%) 1.0 <0.001
30-60 36/55 (65.5%) 2.2 (1.3-3.5)
> 60 12/15 (80.0%) 2.7 (1.6-4.5)
Classification of dengue
Dengue 22/62 (35.5%) 1.0 <0.001
Dengue with warning signs 34/45 (75.6%) 2.1 (1.5-3.1)
Severe dengue 5/6 (83.3%) 2.4 (1.4-3.8)
Hospitalization
No 27/62 (43.6%) 1.0 0.024
Yes 32/49 (65.3%) 1.5 (1.1-2.1)
Bleeding/thrombocytopenia
No 36/78 (46.2%) 1.0 0.013
Yes 25/35 (71.4%) 1.6 (1.1-2.1)
Pre-syncope/lethargy/mental confusion/sleepiness
No 57/105 (54.3%) 1.0 1.000
Yes 4/8 (50.0%) 0.9 (0.5-1.9)
Abdominal pain/hepatomegaly
No 48/94 (51.1%) 1.0 0.166
Yes 13/19 (68.4%) 1.3 (0.9-1.9)
Shock/signs of shock
No 58/109 (53.2%) 1.0 0.623
Yes 3/4 (75.0%) 1.4 (0.8-2.6)
Respiratory distress
No 54/105 (51.4%) 1.0 0.048
Yes 7/8 (87.5%) 1.7 (1.2-2.4)
Persistent vomiting
No 55/106 (51.9%) 1.0 0.122
Yes 6/7 (85.7%) 1.7 (1.0-2.4)
Respiratory failure
No 59/110 (53.6%) 1.0 1.000
Yes 2/3 (66.7%) 1.2 (0.6-2.8)
Comorbidity
No 20/49 (40.8%) 1.0 0.017
Yes 40/63 (63.5%) 1.6 (1.1-2.3)
1RR (95% CI): relative risk with 95% confidence interval. 2Classical chi-square test or Fisher exact test.
Teixeira et al.
Rev Inst Med Trop São Paulo. 2017;59:e65Page 8 of 9
annual cost of the disease of US$ 8.9 billion. Considering 
published data on the persistence of dengue symptoms, Tiga 
et al.3 estimated a 43% increase in the impact attributed to 
persistent symptoms over previous estimates. 
Other variables associated with persistent symptoms 
are gender and age. An association of female gender and 
advanced age with the presence of persistent symptoms 
has been observed in other studies3,11,12. This would be 
consistent with the view that older patients have a lower 
regenerative capacity of affected tissues and would, 
therefore, take longer to recover from the disease. In the 
case of female gender, other factors such as reproductive 
function, genetic constitution and psychosomatic factors 
need to considered. In the present study, the variables 
associated with the progression to persistent symptoms 
were older age, dengue with warning signs, severe 
dengue, hospitalization, presence of bleeding, respiratory 
distress and comorbidities. No association with gender 
was observed. This result may be explained by the size 
of the analyzed sample, especially the small number of 
patients with severe dengue and the impact of the disease 
in older individuals who are more frequently affected by 
comorbidities and are more likely to be hospitalized. 
Regarding the results of the laboratory tests, most 
patients classified as dengue with warning signs showed 
no alterations in hematocrit on admission or during 
evolution of the disease. In the case of patients with normal 
hematocrit, this parameter loses its utility as a marker of 
adequate hydration as recommended by the WHO13,14. On 
the other hand, alterations in hematocrit were significantly 
associated with severity. Thus, hematocrit alterations should 
be considered if present, but their absence does not exclude 
severe disease. 
Liver involvement has been reported to be relatively 
common in dengue and is characterized by necrosis and 
apoptosis of hepatocytes and Kupffer cells induced by the 
dengue virus itself18. Transaminase levels as a measure 
of liver damage have been used in several studies and 
increased levels of these enzymes have been associated 
with a poor prognosis19-21. Increased liver enzymes were 
observed in 60% of the patients and increased ALT levels 
were associated with the progression to persistent symptoms 
of dengue. 
A limitation of the present study is the fact that only 
patients seen at a tertiary hospital were included. Thus, 
the present results may not reflect what happens to cases 
seen in primary care. To analyze the presence or absence 
of hospitalization, only the records of the HC/UFTM and 
the information provided by the patients were analyzed 
as it was not possible to track hospitalizations in other 
medical units. Regarding the characterization of persistent 
symptoms, the report of the patients was subjective on many 
occasions (e.g., limitation of physical effort), a fact that 
impairs the collection of more precise information about 
the intensity of symptoms. Furthermore, the frequency of 
persistent symptoms might have been overestimated since 
only patients who were regularly seen at the HC/UFTM 
until medical discharge were included.
The present results confirm the persistence of symptoms 
attributed to dengue for prolonged periods and its association 
with advanced age and severity of the disease. Further studies 
are needed to characterize the physiopathogenic factors of 
the disease associated with the progression to persistent 
symptoms, as well as the repercussion of these symptoms on 
the social and economic life of affected patients. 
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